

Issued by JPAC: 16 March 2022

Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 13 - 2022

Infertility

This change applies to all the Tissue and Cell Donor Selection Guidelines

Infertility Entry in the Bone Marrow & Peripheral Blood Stem Cell Donor Selection Guidelines

Please amend the following sections of this entry:

| | |
|--------------------------------|---|
| <i>Obligatory:</i> | <p>Must not donate if:</p> <ul style="list-style-type: none"> a) Under investigation. b) Less than 12 weeks after completion of treatment with clomiphene (Clomid). c) Less than 12 weeks after completion of treatment with tamoxifen. d) Has ever been given human gonadotrophin of pituitary origin. e) If donor knows that they have ever been treated with Metrodin HP®. |
| <i>Additional Information:</i> | <p>The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy.</p> <p>There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.</p> |

| | |
|---------------------------|--|
| <i>Reason for Change:</i> | <p>To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.</p> <p>To update the 'additional information' section with a statement that there is no evidence that transplanted eggs or embryos might lead to spread of vCJD</p> |
|---------------------------|--|

Infertility Entry in the Cord Blood Donor Selection Guidelines

Please amend the following sections of this entry:

| | |
|--------------------------------|---|
| <i>Obligatory:</i> | <p>Must not donate if:</p> <p>a) Has ever been given human gonadotrophin of pituitary origin.</p> <p>b) If donor knows that they have ever been treated with Metrodin HP®.</p> |
| <i>Additional Information:</i> | <p>The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy.</p> <p>There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.</p> |
| <i>Reason for Change:</i> | <p>To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.</p> <p>To update the 'additional information' section with a statement that there is no evidence that transplanted eggs or embryos might lead to spread of vCJD</p> |

Infertility Entry in the Deceased and Living Donor Selection Guidelines

Please amend the following sections of this entry:

| | |
|--------------------------------|---|
| <i>Obligatory:</i> | <p>Must not donate if:</p> <p>a) Has ever been given human gonadotrophin of pituitary origin.</p> <p>b) If donor knows that they have ever been treated with Metrodin HP®.</p> |
| <i>Additional Information:</i> | <p>The use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) had stopped in the UK by 1986. The situation in other countries varied so specific dates cannot be given. The 12 week period is an additional safeguard to avoid taking a donation early in a pregnancy.</p> <p>There is a concern that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>There is no evidence that transfer of tissues (eggs or embryos) between individuals might lead to the spread of vCJD.</p> <p>Metrodin HP® was withdrawn by the Committee on Safety of Medicines in 2003 and following advice from the Medicines and Healthcare products Regulatory Agency the precautionary principle has been applied to withdraw donors who have been treated with this product. Donors treated for infertility after 2003 in the UK will not have been treated with this product.</p> |
| <i>Reason for Change:</i> | <p>To add additional information to clarify when the use of human gonadotrophin of pituitary origin (follicle-stimulating hormone (FSH) and luteinizing hormone (LH)) ceased in the UK.</p> <p>To update the 'additional information' section with a statement that there is no evidence that transplantation of eggs or embryos might lead to spread of vCJD</p> |

Sheila MacLennan

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee
 ☎ Direct Dial : (0113) 820 8638 ✉ sheila.maclennan@nhsbt.nhs.uk